2022 World Conference on Lung Cancer (ePosters)-EP08.02-096. Different Epidermal Growth Factor Receptor Inhibitor Generations Plus Antiangiogenic for EGFR-Mutated NSCLC: A Meta-Analysis

EP08.02-096. Different Epidermal Growth Factor Receptor Inhibitor Generations Plus Antiangiogenic for EGFR-Mutated NSCLC: A Meta-Analysis

Back to course

Pdf Summary

Three generations of EGFR-TKIs have been developed to treat advanced non-small cell lung cancer (NSCLC) patients with EGFR-activating mutations. However, no meta-analysis has compared the efficacy and safety of different generations of EGFR-TKIs in combination with antiangiogenic agents. <br /><br />A meta-analysis was conducted on 13 trials with a total of 1775 patients. The combination of EGFR-TKIs and antiangiogenic agents showed significantly longer progression-free survival (PFS) compared to monotherapy. However, there was no significant difference in overall survival (OS), objective response rate (ORR), and disease control rate (DCR) between the combination group and the monotherapy group in both the first and third generations of EGFR-TKIs. <br /><br />The combination therapy was associated with a higher incidence of grade 3 or higher adverse events compared to monotherapy in both generations. The benefit of combination therapy was seen to be greater in first-line treatment compared to other lines of treatment. Smokers and non-Asian patients also experienced better PFS outcomes with combination therapy. <br /><br />In conclusion, the combination of first-generation EGFR-TKIs and antiangiogenic agents significantly improved PFS in EGFR-mutated NSCLC. However, there was no significant difference in OS, ORR, and DCR between the combination therapy and monotherapy groups in both generations of EGFR-TKIs. It is important to consider the increased risk of grade 3 or higher adverse events with combination therapy.

Asset Subtitle

Leen Al-Kraimeen

Meta Tag

Speaker Leen Al-Kraimeen

Topic Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

Keywords

EGFR-TKIs

non-small cell lung cancer

NSCLC

EGFR-activating mutations

meta-analysis

antiangiogenic agents

progression-free survival

overall survival

objective response rate

disease control rate